Cargando…

The prognostic benefit from intermediate-dose cytarabine as consolidation therapy varies by cytogenetic subtype in t(8;21) acute myeloid leukemia: a retrospective cohort study

BACKGROUND: Patients with different karyotypes had different prognosis in t(8;21) acute myeloid leukemia (AML). Cytarabine (Ara-C) plays an important role as consolidation therapy in t(8;21) AML. T(8;21) AML patients with different karyotypes responded differently to post-remission therapy with Ara-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Guofeng, Yang, Jiaqi, Cao, Fuliang, Zhou, Wei, Gong, Dan, Liu, Liren, Zhou, Dejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469173/ https://www.ncbi.nlm.nih.gov/pubmed/36111020 http://dx.doi.org/10.21037/atm-22-2965

Ejemplares similares

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

Retrospective Comparison of Fludarabine in Combination With Intermediate-Dose Cytarabine Versus High-Dose Cytarabine As Consolidation Therapies for Acute Myeloid Leukemia
por: Zhang, Wenjun, et al.
Publicado: (2014)

Methylation-associated silencing of BASP1 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Zhou, Lei, et al.
Publicado: (2018)

Role of CD19 and specific KIT‐D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities
por: Wang, Biao, et al.
Publicado: (2020)

Benefit of intermediate-dose cytarabine-containing induction in molecular subgroups of acute myeloid leukemia
por: Wei, Hui, et al.
Publicado: (2020)

Acute Myeloid Leukemia with the t(8;21) Translocation: Clinical Consequences and Biological Implications
por: Reikvam, Håkon, et al.
Publicado: (2011)

Translocation (8;21) acute myeloid leukemia presenting as severe aplastic anemia
por: Purev, Enkhtsetseg, et al.
Publicado: (2014)

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Modelling t(8;21) acute myeloid leukaemia ‐ What have we learned?
por: Chin, Paulynn Suyin, et al.
Publicado: (2020)

Association of a cytarabine chemosensitivity related gene expression signature with survival in cytogenetically normal acute myeloid leukemia
por: Yan, Han, et al.
Publicado: (2016)

Single-cell RNA sequencing of t(8;21) acute myeloid leukemia for risk prediction
por: Xiong, Qian, et al.
Publicado: (2020)

Epigenetic silencing of UBXN8 contributes to leukemogenesis in t(8;21) acute myeloid leukemia
por: Yang, Erna, et al.
Publicado: (2021)

Repurposing cabozantinib with therapeutic potential in KIT-driven t(8;21) acute myeloid leukaemias
por: Su, Kuan-Wei, et al.
Publicado: (2021)

Possible benefit of consolidation therapy with high-dose cytarabine on overall survival of adults with non-promyelocytic acute myeloid leukemia
por: Azevedo, M.C., et al.
Publicado: (2014)

Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia
por: Pullarkat, Sheeja T., et al.
Publicado: (2009)

A case of acute myeloid leukemia-M2 with trisomy 4 in addition to t(8;21)
por: Trivedi, P. J., et al.
Publicado: (2008)

Standard-Intensity Induction and Intermediate/High-Dose Cytarabine Consolidation Can Improve Survival for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: A Retrospective Cohort Study
por: Wang, Li, et al.
Publicado: (2022)

Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase‐3‐mediated cleavage of the AML1‐ETO oncoprotein
por: Cao, Jiang, et al.
Publicado: (2016)

Isolated Pancreatic Myeloid Sarcoma Associated with t(8;21)/RUNX1-RUNX1T1 Rearrangement
por: Tokunaga, Kenji, et al.
Publicado: (2017)

Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21)
por: Qin, Ya-Zhen, et al.
Publicado: (2018)

Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21)
por: Lu, Lianghao, et al.
Publicado: (2018)

High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia
por: Yang, Lu, et al.
Publicado: (2019)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

A new inducible model for t(8;21) AML
por: Mulloy, James C
Publicado: (2013)

Risk factors for post-transplant relapse and survival in younger adult patients with t(8;21)(q22;q22) acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: A multicenter retrospective study
por: Zhou, Wei, et al.
Publicado: (2023)

t(8;21) Acute Myeloid Leukemia as a Paradigm for the Understanding of Leukemogenesis at the Level of Gene Regulation and Chromatin Programming
por: Kellaway, Sophie, et al.
Publicado: (2020)

Nanoparticle-mediated targeting of the fusion gene RUNX1/ETO in t(8;21)-positive acute myeloid leukaemia
por: Issa, Hasan, et al.
Publicado: (2023)

DNA methylation landscape reveals LIN7A as a decitabine-responsive marker in patients with t(8;21) acute myeloid leukemia
por: He, Shujiao, et al.
Publicado: (2023)

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1)
por: Meyer, Tatjana, et al.
Publicado: (2019)

Successful Outcome of a Case of Acute Myeloid Leukemia with t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis
por: Meng, Guangqiang, et al.
Publicado: (2019)

Low IL7R Expression at Diagnosis Predicted Relapse in Adult Acute Myeloid Leukemia Patients With t(8;21)
por: Xu, Nan, et al.
Publicado: (2022)

Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis
por: Wu, Di, et al.
Publicado: (2017)

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia
por: Jaramillo, S, et al.
Publicado: (2017)

Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
por: Salmon, Jessica M, et al.
Publicado: (2015)

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study
por: Ye, Li, et al.
Publicado: (2021)

JAK inhibitors suppress t(8;21) fusion protein-induced leukemia
por: Lo, Miao-Chia, et al.
Publicado: (2013)

我如何治疗t（8；21）急性髓系白血病
Publicado: (2017)

POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature
por: Fortier, Julie M., et al.
Publicado: (2010)

High Expression of c-kit mRNA Predicts Unfavorable Outcome in Adult Patients with t(8;21) Acute Myeloid Leukemia
por: Gao, Xiaoning, et al.
Publicado: (2015)

Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
por: Ustun, Celalettin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6kpu1pikgdl3hol4s9j48p4jip